| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinocerebellar Ataxias | 75 | 2023 | 233 | 15.550 |
Why?
|
| Machado-Joseph Disease | 21 | 2023 | 21 | 4.980 |
Why?
|
| Microsatellite Repeats | 17 | 2022 | 575 | 3.720 |
Why?
|
| Cerebellar Ataxia | 9 | 2023 | 72 | 3.330 |
Why?
|
| Myotonic Dystrophy | 18 | 2023 | 151 | 3.310 |
Why?
|
| Trinucleotide Repeat Expansion | 28 | 2022 | 132 | 3.200 |
Why?
|
| DNA Repeat Expansion | 30 | 2022 | 64 | 2.890 |
Why?
|
| Ataxin-10 | 16 | 2021 | 19 | 2.740 |
Why?
|
| Ataxia | 12 | 2023 | 176 | 2.310 |
Why?
|
| RNA | 8 | 2023 | 1013 | 1.640 |
Why?
|
| Nerve Tissue Proteins | 21 | 2023 | 1491 | 1.570 |
Why?
|
| Induced Pluripotent Stem Cells | 6 | 2020 | 203 | 1.410 |
Why?
|
| Epilepsy | 7 | 2019 | 883 | 1.250 |
Why?
|
| Cerebellum | 10 | 2023 | 449 | 1.220 |
Why?
|
| Neural Stem Cells | 5 | 2018 | 181 | 1.140 |
Why?
|
| Spinocerebellar Degenerations | 5 | 2021 | 21 | 1.050 |
Why?
|
| Purkinje Cells | 2 | 2019 | 143 | 1.040 |
Why?
|
| Ataxin-3 | 9 | 2021 | 10 | 1.000 |
Why?
|
| Friedreich Ataxia | 10 | 2021 | 40 | 0.990 |
Why?
|
| Phenotype | 23 | 2021 | 6295 | 0.860 |
Why?
|
| DNA, Catalytic | 1 | 2021 | 4 | 0.820 |
Why?
|
| Nerve Degeneration | 2 | 2013 | 148 | 0.810 |
Why?
|
| Neuromuscular Diseases | 2 | 2017 | 63 | 0.790 |
Why?
|
| White Matter | 2 | 2020 | 195 | 0.760 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 7 | 2010 | 362 | 0.760 |
Why?
|
| Genetic Testing | 7 | 2019 | 1589 | 0.760 |
Why?
|
| Myelin Sheath | 1 | 2020 | 149 | 0.700 |
Why?
|
| Tremor | 5 | 2022 | 128 | 0.700 |
Why?
|
| Brazil | 12 | 2020 | 165 | 0.700 |
Why?
|
| Humans | 150 | 2023 | 261506 | 0.690 |
Why?
|
| Genotype | 13 | 2020 | 4109 | 0.680 |
Why?
|
| Oligonucleotides | 2 | 2019 | 227 | 0.640 |
Why?
|
| Age of Onset | 23 | 2020 | 827 | 0.630 |
Why?
|
| Repressor Proteins | 9 | 2020 | 1664 | 0.630 |
Why?
|
| Mutation | 23 | 2020 | 15179 | 0.620 |
Why?
|
| Multicenter Studies as Topic | 2 | 2018 | 543 | 0.610 |
Why?
|
| Indians, South American | 2 | 2015 | 14 | 0.610 |
Why?
|
| Communication Disorders | 1 | 2017 | 8 | 0.610 |
Why?
|
| Huntington Disease | 8 | 2014 | 135 | 0.610 |
Why?
|
| Genome, Human | 4 | 2015 | 1869 | 0.600 |
Why?
|
| Gene Frequency | 3 | 2019 | 1163 | 0.590 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2017 | 30 | 0.590 |
Why?
|
| Liposomes | 1 | 2019 | 684 | 0.580 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 4 | 2020 | 129 | 0.580 |
Why?
|
| Inheritance Patterns | 1 | 2017 | 139 | 0.580 |
Why?
|
| Metalloendopeptidases | 1 | 2017 | 170 | 0.570 |
Why?
|
| DNA Repair Enzymes | 4 | 2020 | 237 | 0.550 |
Why?
|
| Peptides | 2 | 2021 | 1479 | 0.550 |
Why?
|
| Myotonic Disorders | 2 | 2013 | 13 | 0.510 |
Why?
|
| Nervous System Diseases | 2 | 2017 | 500 | 0.510 |
Why?
|
| Adult | 62 | 2023 | 77950 | 0.490 |
Why?
|
| Pluripotent Stem Cells | 1 | 2015 | 123 | 0.480 |
Why?
|
| Indians, Central American | 1 | 2013 | 3 | 0.480 |
Why?
|
| Male | 76 | 2021 | 123000 | 0.470 |
Why?
|
| Fibroblasts | 4 | 2019 | 1682 | 0.470 |
Why?
|
| Pedigree | 12 | 2021 | 1890 | 0.450 |
Why?
|
| Dermis | 1 | 2013 | 65 | 0.450 |
Why?
|
| Emotions | 1 | 2017 | 562 | 0.450 |
Why?
|
| Middle Aged | 59 | 2021 | 86204 | 0.440 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 534 | 0.420 |
Why?
|
| Eye Movements | 1 | 2012 | 116 | 0.420 |
Why?
|
| Gait | 2 | 2020 | 165 | 0.420 |
Why?
|
| Motor Neurons | 1 | 2012 | 138 | 0.410 |
Why?
|
| Trinucleotide Repeats | 8 | 2017 | 106 | 0.410 |
Why?
|
| Alleles | 14 | 2018 | 2437 | 0.400 |
Why?
|
| Female | 70 | 2021 | 141928 | 0.380 |
Why?
|
| Brain | 7 | 2020 | 4113 | 0.380 |
Why?
|
| Neurogenesis | 1 | 2012 | 238 | 0.370 |
Why?
|
| Cell Differentiation | 4 | 2018 | 4078 | 0.370 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2018 | 156 | 0.360 |
Why?
|
| Shaw Potassium Channels | 3 | 2013 | 10 | 0.350 |
Why?
|
| RNA-Binding Proteins | 5 | 2018 | 984 | 0.340 |
Why?
|
| Seizures | 2 | 2011 | 989 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2018 | 4549 | 0.330 |
Why?
|
| Myotonin-Protein Kinase | 5 | 2023 | 36 | 0.330 |
Why?
|
| Migraine Disorders | 1 | 2010 | 79 | 0.330 |
Why?
|
| Motor Activity | 2 | 2016 | 693 | 0.330 |
Why?
|
| Introns | 4 | 2021 | 432 | 0.330 |
Why?
|
| Base Sequence | 7 | 2017 | 4917 | 0.320 |
Why?
|
| Nuclear Proteins | 4 | 2015 | 3343 | 0.310 |
Why?
|
| Disease Progression | 12 | 2022 | 6682 | 0.310 |
Why?
|
| Alternative Splicing | 3 | 2020 | 584 | 0.310 |
Why?
|
| Cell Line | 8 | 2020 | 5114 | 0.290 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2006 | 32 | 0.280 |
Why?
|
| Neurites | 1 | 2006 | 63 | 0.280 |
Why?
|
| Olfaction Disorders | 2 | 2019 | 26 | 0.280 |
Why?
|
| Depressive Disorder | 1 | 2010 | 557 | 0.270 |
Why?
|
| Mexico | 7 | 2020 | 259 | 0.260 |
Why?
|
| Ataxins | 2 | 2017 | 91 | 0.260 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 2283 | 0.260 |
Why?
|
| Polymorphism, Genetic | 3 | 2013 | 1450 | 0.250 |
Why?
|
| Parkinson Disease | 4 | 2019 | 708 | 0.250 |
Why?
|
| Myotonia Congenita | 3 | 2008 | 6 | 0.240 |
Why?
|
| Chloride Channels | 3 | 2008 | 60 | 0.230 |
Why?
|
| Peru | 2 | 2021 | 52 | 0.230 |
Why?
|
| Activities of Daily Living | 3 | 2022 | 552 | 0.230 |
Why?
|
| Carrier Proteins | 1 | 2011 | 2022 | 0.230 |
Why?
|
| Dystonia | 2 | 2017 | 163 | 0.220 |
Why?
|
| Gene Expression | 3 | 2017 | 3570 | 0.220 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 333 | 0.220 |
Why?
|
| Founder Effect | 2 | 2020 | 42 | 0.210 |
Why?
|
| Family Health | 5 | 2013 | 325 | 0.210 |
Why?
|
| Neurology | 1 | 2003 | 113 | 0.210 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2023 | 248 | 0.210 |
Why?
|
| Animals | 18 | 2021 | 59536 | 0.200 |
Why?
|
| Ubiquinone | 2 | 2014 | 37 | 0.200 |
Why?
|
| Tourette Syndrome | 1 | 2003 | 130 | 0.200 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 1945 | 0.200 |
Why?
|
| Huntingtin Protein | 2 | 2019 | 60 | 0.200 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2021 | 28 | 0.200 |
Why?
|
| DNA | 3 | 2011 | 2693 | 0.200 |
Why?
|
| Prospective Studies | 7 | 2023 | 12873 | 0.190 |
Why?
|
| HEK293 Cells | 3 | 2021 | 1489 | 0.190 |
Why?
|
| Comorbidity | 3 | 2020 | 2352 | 0.190 |
Why?
|
| Ataxin-2 | 2 | 2020 | 7 | 0.190 |
Why?
|
| Replication Protein C | 1 | 2020 | 18 | 0.190 |
Why?
|
| Multiple System Atrophy | 1 | 2020 | 19 | 0.190 |
Why?
|
| Nucleic Acid Conformation | 2 | 2017 | 279 | 0.190 |
Why?
|
| C9orf72 Protein | 2 | 2017 | 21 | 0.190 |
Why?
|
| Fragile X Syndrome | 1 | 2022 | 150 | 0.190 |
Why?
|
| Stereotaxic Techniques | 1 | 2021 | 172 | 0.190 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2003 | 362 | 0.190 |
Why?
|
| Electrophoresis, Capillary | 1 | 2020 | 31 | 0.190 |
Why?
|
| Haplotypes | 6 | 2013 | 856 | 0.190 |
Why?
|
| Pyramidal Tracts | 1 | 2020 | 57 | 0.180 |
Why?
|
| Mutant Proteins | 2 | 2019 | 234 | 0.180 |
Why?
|
| Rett Syndrome | 1 | 2003 | 262 | 0.180 |
Why?
|
| Gene Silencing | 2 | 2021 | 837 | 0.180 |
Why?
|
| 3' Untranslated Regions | 3 | 2018 | 343 | 0.180 |
Why?
|
| Cerebellar Diseases | 2 | 2018 | 89 | 0.170 |
Why?
|
| DNA End-Joining Repair | 1 | 2020 | 86 | 0.170 |
Why?
|
| Severity of Illness Index | 11 | 2020 | 4320 | 0.170 |
Why?
|
| Codon, Terminator | 2 | 2012 | 42 | 0.170 |
Why?
|
| Genomic Instability | 3 | 2013 | 519 | 0.170 |
Why?
|
| RNA Polymerase II | 1 | 2020 | 182 | 0.170 |
Why?
|
| Postural Balance | 1 | 2020 | 151 | 0.170 |
Why?
|
| Cells, Cultured | 4 | 2017 | 5637 | 0.170 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2018 | 15 | 0.170 |
Why?
|
| Young Adult | 13 | 2019 | 21445 | 0.170 |
Why?
|
| Scoliosis | 1 | 2020 | 139 | 0.170 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 264 | 0.170 |
Why?
|
| RNA Splicing | 3 | 2018 | 370 | 0.170 |
Why?
|
| Depression | 3 | 2020 | 1715 | 0.170 |
Why?
|
| Mice, Inbred ICR | 1 | 2019 | 239 | 0.160 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2018 | 8 | 0.160 |
Why?
|
| Receptors, LDL | 1 | 2019 | 109 | 0.160 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 303 | 0.160 |
Why?
|
| Mitochondrial Proteins | 1 | 2020 | 369 | 0.160 |
Why?
|
| Curriculum | 1 | 2003 | 860 | 0.160 |
Why?
|
| Frontotemporal Dementia | 1 | 2018 | 40 | 0.160 |
Why?
|
| Microvessels | 1 | 2019 | 135 | 0.160 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.160 |
Why?
|
| Smell | 1 | 2019 | 125 | 0.160 |
Why?
|
| Genes, Dominant | 3 | 2013 | 331 | 0.150 |
Why?
|
| ran GTP-Binding Protein | 1 | 2017 | 34 | 0.150 |
Why?
|
| Molecular Sequence Data | 7 | 2015 | 6089 | 0.150 |
Why?
|
| Biomarkers | 4 | 2023 | 5047 | 0.150 |
Why?
|
| Stem Cell Transplantation | 2 | 2016 | 1360 | 0.150 |
Why?
|
| Transfection | 3 | 2018 | 2944 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 2003 | 671 | 0.150 |
Why?
|
| Polysomnography | 1 | 2018 | 155 | 0.150 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2017 | 85 | 0.150 |
Why?
|
| Cohort Studies | 8 | 2018 | 9244 | 0.150 |
Why?
|
| RNA, Antisense | 1 | 2017 | 69 | 0.150 |
Why?
|
| Mice, Transgenic | 5 | 2019 | 4143 | 0.150 |
Why?
|
| Sensorimotor Cortex | 1 | 2016 | 22 | 0.140 |
Why?
|
| Latin America | 2 | 2013 | 115 | 0.140 |
Why?
|
| Channelopathies | 1 | 2016 | 10 | 0.140 |
Why?
|
| Retina | 2 | 2017 | 532 | 0.140 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 447 | 0.140 |
Why?
|
| China | 4 | 2021 | 606 | 0.140 |
Why?
|
| Genetic Association Studies | 4 | 2013 | 1084 | 0.140 |
Why?
|
| Mitomycin | 2 | 2015 | 208 | 0.130 |
Why?
|
| Case-Control Studies | 7 | 2020 | 6100 | 0.130 |
Why?
|
| DNA Repair | 3 | 2019 | 1872 | 0.130 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 151 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 4314 | 0.130 |
Why?
|
| Tomography, Optical Coherence | 2 | 2017 | 501 | 0.130 |
Why?
|
| Genes, Recessive | 2 | 2013 | 200 | 0.130 |
Why?
|
| Ataxia Telangiectasia | 1 | 2015 | 62 | 0.130 |
Why?
|
| Body Composition | 1 | 2018 | 595 | 0.130 |
Why?
|
| Mice | 10 | 2021 | 34495 | 0.130 |
Why?
|
| Ocular Motility Disorders | 1 | 2015 | 47 | 0.130 |
Why?
|
| RNA, Messenger | 3 | 2023 | 6150 | 0.130 |
Why?
|
| Protein Kinase C-delta | 2 | 2015 | 42 | 0.130 |
Why?
|
| Aged | 23 | 2020 | 70117 | 0.130 |
Why?
|
| Iron-Binding Proteins | 4 | 2012 | 35 | 0.120 |
Why?
|
| Genetic Therapy | 3 | 2018 | 1616 | 0.120 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 348 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 7 | 2015 | 3203 | 0.120 |
Why?
|
| Cell Nucleus | 3 | 2016 | 1620 | 0.120 |
Why?
|
| Protein Binding | 5 | 2019 | 3438 | 0.120 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 29902 | 0.120 |
Why?
|
| Sound Localization | 1 | 2013 | 1 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2012 | 108 | 0.120 |
Why?
|
| Neoplasms | 1 | 2020 | 15193 | 0.120 |
Why?
|
| Histidine | 1 | 2013 | 91 | 0.120 |
Why?
|
| Muscle, Skeletal | 3 | 2018 | 1270 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2013 | 332 | 0.120 |
Why?
|
| Muscular Dystrophies | 1 | 2013 | 51 | 0.120 |
Why?
|
| Indians, North American | 1 | 2013 | 87 | 0.120 |
Why?
|
| Protein Biosynthesis | 1 | 2017 | 889 | 0.110 |
Why?
|
| Receptors, Dopamine | 1 | 2013 | 42 | 0.110 |
Why?
|
| Chromosome Mapping | 2 | 2015 | 1471 | 0.110 |
Why?
|
| Suicidal Ideation | 1 | 2015 | 207 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 526 | 0.110 |
Why?
|
| Receptors, Kainic Acid | 1 | 2012 | 4 | 0.110 |
Why?
|
| Adolescent | 12 | 2019 | 31252 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 5539 | 0.110 |
Why?
|
| Atrophy | 1 | 2013 | 261 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2019 | 1048 | 0.110 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 3154 | 0.110 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2012 | 107 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2003 | 1375 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 4 | 2013 | 2483 | 0.110 |
Why?
|
| Mitosis | 1 | 2015 | 615 | 0.110 |
Why?
|
| Anticipation, Genetic | 2 | 2013 | 3 | 0.110 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 394 | 0.110 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2012 | 123 | 0.110 |
Why?
|
| Olfactory Perception | 1 | 2012 | 31 | 0.110 |
Why?
|
| Methylprednisolone | 1 | 2013 | 193 | 0.100 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2012 | 110 | 0.100 |
Why?
|
| Alcoholic Beverages | 1 | 2011 | 22 | 0.100 |
Why?
|
| Proteins | 2 | 2021 | 1963 | 0.100 |
Why?
|
| Genetic Variation | 3 | 2017 | 2086 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2011 | 4821 | 0.100 |
Why?
|
| Vision Disorders | 1 | 2013 | 245 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2012 | 270 | 0.100 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 311 | 0.100 |
Why?
|
| TATA-Box Binding Protein | 2 | 2007 | 38 | 0.100 |
Why?
|
| Cellular Reprogramming | 1 | 2012 | 189 | 0.090 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2010 | 28 | 0.090 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2013 | 259 | 0.090 |
Why?
|
| Arginine | 1 | 2013 | 500 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 266 | 0.090 |
Why?
|
| Family | 1 | 2014 | 736 | 0.090 |
Why?
|
| Child | 11 | 2014 | 29154 | 0.090 |
Why?
|
| DNA Damage | 2 | 2015 | 1954 | 0.090 |
Why?
|
| Quality of Life | 2 | 2018 | 4532 | 0.090 |
Why?
|
| Genomics | 1 | 2021 | 2738 | 0.090 |
Why?
|
| Serine | 1 | 2011 | 388 | 0.090 |
Why?
|
| Aging | 1 | 2018 | 1582 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 7702 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 2232 | 0.090 |
Why?
|
| Models, Genetic | 2 | 2020 | 1113 | 0.090 |
Why?
|
| Glycine | 1 | 2011 | 289 | 0.090 |
Why?
|
| Cell Cycle | 1 | 2015 | 2084 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2013 | 629 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2016 | 806 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2018 | 2669 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 551 | 0.080 |
Why?
|
| Genetic Markers | 4 | 2020 | 974 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 810 | 0.080 |
Why?
|
| Self Medication | 1 | 2007 | 23 | 0.080 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 1879 | 0.080 |
Why?
|
| Exome | 1 | 2013 | 1239 | 0.080 |
Why?
|
| Nonprescription Drugs | 1 | 2007 | 52 | 0.080 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 3719 | 0.080 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2006 | 19 | 0.070 |
Why?
|
| PC12 Cells | 1 | 2006 | 46 | 0.070 |
Why?
|
| Nerve Growth Factor | 1 | 2006 | 45 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 2291 | 0.070 |
Why?
|
| Calcium Channels | 1 | 2007 | 197 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 14551 | 0.070 |
Why?
|
| Mitochondria | 2 | 2010 | 1282 | 0.070 |
Why?
|
| Penetrance | 2 | 2021 | 126 | 0.070 |
Why?
|
| COS Cells | 1 | 2006 | 377 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2006 | 179 | 0.070 |
Why?
|
| alpha-Synuclein | 1 | 2006 | 118 | 0.070 |
Why?
|
| Genetics, Population | 3 | 2013 | 242 | 0.060 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2005 | 33 | 0.060 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 7222 | 0.060 |
Why?
|
| Genetic Linkage | 3 | 2013 | 512 | 0.060 |
Why?
|
| Leukocytes | 2 | 2004 | 422 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 2019 | 1271 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 590 | 0.060 |
Why?
|
| Genetic Carrier Screening | 1 | 2004 | 92 | 0.060 |
Why?
|
| Antioxidants | 1 | 2007 | 507 | 0.060 |
Why?
|
| Glycogen Phosphorylase, Muscle Form | 1 | 2003 | 1 | 0.060 |
Why?
|
| Glycogen Storage Disease Type V | 1 | 2003 | 2 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 460 | 0.060 |
Why?
|
| Muscles | 2 | 2020 | 416 | 0.060 |
Why?
|
| Specialty Boards | 1 | 2003 | 46 | 0.060 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 216 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2018 | 3639 | 0.060 |
Why?
|
| DNA, Superhelical | 1 | 2003 | 23 | 0.060 |
Why?
|
| Animals, Genetically Modified | 2 | 2020 | 406 | 0.060 |
Why?
|
| Accreditation | 1 | 2003 | 126 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2011 | 2819 | 0.060 |
Why?
|
| Disease Transmission, Infectious | 1 | 2004 | 94 | 0.060 |
Why?
|
| Prevalence | 3 | 2017 | 3260 | 0.060 |
Why?
|
| Epilepsy, Complex Partial | 1 | 2002 | 18 | 0.060 |
Why?
|
| Neural Pathways | 2 | 2016 | 298 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2023 | 113 | 0.050 |
Why?
|
| Base Composition | 2 | 2018 | 92 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2003 | 172 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2004 | 147 | 0.050 |
Why?
|
| Minocycline | 1 | 2004 | 182 | 0.050 |
Why?
|
| Myasthenia Gravis, Autoimmune, Experimental | 1 | 2002 | 6 | 0.050 |
Why?
|
| Age Distribution | 1 | 2004 | 698 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 72 | 0.050 |
Why?
|
| Electroencephalography | 2 | 2021 | 898 | 0.050 |
Why?
|
| Essential Tremor | 1 | 2003 | 85 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2015 | 7226 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2003 | 460 | 0.050 |
Why?
|
| Receptors, Cholinergic | 1 | 2002 | 84 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2023 | 2588 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 848 | 0.050 |
Why?
|
| Germ Cells | 1 | 2004 | 335 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2020 | 37905 | 0.050 |
Why?
|
| Computers | 1 | 2022 | 141 | 0.050 |
Why?
|
| ras Proteins | 1 | 2006 | 770 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2021 | 27 | 0.050 |
Why?
|
| Spermatozoa | 1 | 2004 | 315 | 0.050 |
Why?
|
| Rats | 2 | 2011 | 6086 | 0.050 |
Why?
|
| Myocytes, Cardiac | 2 | 2018 | 764 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2002 | 182 | 0.050 |
Why?
|
| Carbamazepine | 1 | 2021 | 49 | 0.050 |
Why?
|
| Plasmids | 1 | 2003 | 837 | 0.050 |
Why?
|
| Epileptic Syndromes | 1 | 2021 | 26 | 0.050 |
Why?
|
| Cuba | 1 | 2020 | 10 | 0.050 |
Why?
|
| Neurologic Examination | 2 | 2012 | 245 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2020 | 23 | 0.050 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2003 | 291 | 0.050 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 66 | 0.050 |
Why?
|
| Biostatistics | 1 | 2020 | 20 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2020 | 2508 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2023 | 32848 | 0.050 |
Why?
|
| Apoptosis | 2 | 2015 | 7591 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2022 | 624 | 0.050 |
Why?
|
| Drosophila melanogaster | 1 | 2006 | 829 | 0.050 |
Why?
|
| Polyadenylation | 1 | 2020 | 70 | 0.040 |
Why?
|
| RNA, Long Noncoding | 2 | 2021 | 598 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 117 | 0.040 |
Why?
|
| History, 20th Century | 2 | 2015 | 574 | 0.040 |
Why?
|
| Brain Stem | 1 | 2020 | 175 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2018 | 1643 | 0.040 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2019 | 97 | 0.040 |
Why?
|
| RNA 3' Polyadenylation Signals | 1 | 2018 | 1 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2019 | 151 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2015 | 11965 | 0.040 |
Why?
|
| Quantitative Trait Loci | 2 | 2013 | 374 | 0.040 |
Why?
|
| Chromosome Segregation | 2 | 2011 | 82 | 0.040 |
Why?
|
| Point Mutation | 2 | 2012 | 769 | 0.040 |
Why?
|
| Puerperal Disorders | 1 | 2018 | 41 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2008 | 176 | 0.040 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2017 | 8 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2023 | 1073 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2012 | 5270 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2019 | 240 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2018 | 124 | 0.040 |
Why?
|
| Restless Legs Syndrome | 1 | 2017 | 20 | 0.040 |
Why?
|
| Lymphocytes | 2 | 2018 | 1234 | 0.040 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2020 | 316 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2017 | 5687 | 0.040 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2017 | 67 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 319 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2021 | 431 | 0.040 |
Why?
|
| Anthropometry | 1 | 2018 | 269 | 0.040 |
Why?
|
| Heterozygote | 1 | 2020 | 1020 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 1077 | 0.040 |
Why?
|
| Transcription Activator-Like Effector Nucleases | 1 | 2016 | 6 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 2315 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2018 | 699 | 0.040 |
Why?
|
| Hand Strength | 1 | 2016 | 65 | 0.030 |
Why?
|
| Poly A | 1 | 2016 | 87 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 760 | 0.030 |
Why?
|
| Exons | 2 | 2013 | 1328 | 0.030 |
Why?
|
| Gene Editing | 1 | 2018 | 216 | 0.030 |
Why?
|
| Maps as Topic | 1 | 2015 | 1 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 47 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 690 | 0.030 |
Why?
|
| Cognition | 1 | 2022 | 968 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 2016 | 109 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2015 | 1129 | 0.030 |
Why?
|
| PubMed | 1 | 2015 | 41 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 118 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 323 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2017 | 344 | 0.030 |
Why?
|
| Protein Aggregates | 1 | 2015 | 27 | 0.030 |
Why?
|
| Immunoassay | 1 | 2015 | 216 | 0.030 |
Why?
|
| Gene Targeting | 1 | 2016 | 292 | 0.030 |
Why?
|
| Drosophila | 1 | 2020 | 839 | 0.030 |
Why?
|
| Patient Selection | 2 | 2016 | 2055 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2017 | 238 | 0.030 |
Why?
|
| Teratoma | 1 | 2016 | 236 | 0.030 |
Why?
|
| Philippines | 1 | 2013 | 39 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 2173 | 0.030 |
Why?
|
| Auditory Threshold | 1 | 2013 | 26 | 0.030 |
Why?
|
| Italy | 1 | 2014 | 236 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 2216 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2016 | 481 | 0.030 |
Why?
|
| Neuroacanthocytosis | 1 | 2013 | 1 | 0.030 |
Why?
|
| Hearing | 1 | 2013 | 64 | 0.030 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Myopathies, Nemaline | 1 | 2013 | 9 | 0.030 |
Why?
|
| Contrast Sensitivity | 1 | 2013 | 62 | 0.030 |
Why?
|
| Telangiectasis | 1 | 2013 | 26 | 0.030 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2013 | 40 | 0.030 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2013 | 34 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2015 | 441 | 0.030 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2013 | 15 | 0.030 |
Why?
|
| Optic Atrophy | 1 | 2013 | 46 | 0.030 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2013 | 61 | 0.030 |
Why?
|
| Mammals | 1 | 2015 | 361 | 0.030 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2013 | 63 | 0.030 |
Why?
|
| Muscle Spasticity | 1 | 2013 | 74 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 430 | 0.030 |
Why?
|
| Electromyography | 1 | 2013 | 226 | 0.030 |
Why?
|
| United States | 2 | 2015 | 15433 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2016 | 644 | 0.030 |
Why?
|
| Eye Abnormalities | 1 | 2013 | 118 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2012 | 73 | 0.030 |
Why?
|
| Cues | 1 | 2013 | 192 | 0.030 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2011 | 13 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2013 | 16273 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 144 | 0.030 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2011 | 26 | 0.030 |
Why?
|
| Venezuela | 1 | 2011 | 13 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 6009 | 0.030 |
Why?
|
| Argentina | 1 | 2011 | 72 | 0.030 |
Why?
|
| Myocardium | 1 | 2018 | 1313 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 1914 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2011 | 4233 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 2403 | 0.020 |
Why?
|
| Fatigue | 1 | 2017 | 1239 | 0.020 |
Why?
|
| Transformation, Genetic | 1 | 2011 | 57 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2013 | 842 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 1053 | 0.020 |
Why?
|
| Cell Survival | 1 | 2017 | 3045 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 649 | 0.020 |
Why?
|
| Haploinsufficiency | 1 | 2012 | 294 | 0.020 |
Why?
|
| Species Specificity | 1 | 2011 | 777 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2011 | 201 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 3441 | 0.020 |
Why?
|
| Spectrin | 1 | 2011 | 85 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2017 | 862 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2012 | 304 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2011 | 159 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 844 | 0.020 |
Why?
|
| Speech Disorders | 1 | 2010 | 91 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2011 | 254 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 4971 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 834 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2012 | 443 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 1972 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 436 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2013 | 873 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2011 | 1213 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2011 | 798 | 0.020 |
Why?
|
| Costa Rica | 1 | 2008 | 13 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 2008 | 117 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2011 | 434 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2010 | 311 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2007 | 39 | 0.020 |
Why?
|
| Protein Transport | 1 | 2010 | 734 | 0.020 |
Why?
|
| Walking | 1 | 2010 | 277 | 0.020 |
Why?
|
| Neurons | 1 | 2018 | 2287 | 0.020 |
Why?
|
| Acute Disease | 1 | 2013 | 2422 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2011 | 445 | 0.020 |
Why?
|
| Codon | 1 | 2007 | 241 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 224 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 2359 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 621 | 0.020 |
Why?
|
| Dinucleotide Repeats | 1 | 2006 | 10 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2008 | 249 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2013 | 998 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 4804 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 1143 | 0.020 |
Why?
|
| CELF1 Protein | 1 | 2006 | 46 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 1732 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2006 | 220 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 4053 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2007 | 495 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 644 | 0.020 |
Why?
|
| Intellectual Disability | 1 | 2013 | 1032 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2006 | 682 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 2170 | 0.020 |
Why?
|
| Ethyl Methanesulfonate | 1 | 2004 | 8 | 0.020 |
Why?
|
| Pregnancy | 1 | 2018 | 7573 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2011 | 1516 | 0.020 |
Why?
|
| Mitoxantrone | 1 | 2004 | 216 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2004 | 95 | 0.020 |
Why?
|
| Japan | 1 | 2004 | 227 | 0.020 |
Why?
|
| Eye | 1 | 2006 | 301 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 1037 | 0.010 |
Why?
|
| North America | 1 | 2004 | 314 | 0.010 |
Why?
|
| Fluorescence | 1 | 2004 | 195 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 2265 | 0.010 |
Why?
|
| Microscopy, Atomic Force | 1 | 2003 | 29 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2004 | 261 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 314 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2004 | 176 | 0.010 |
Why?
|
| Base Pairing | 1 | 2003 | 68 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 212 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2012 | 5710 | 0.010 |
Why?
|
| Torpedo | 1 | 2002 | 36 | 0.010 |
Why?
|
| RNA, Untranslated | 1 | 2004 | 237 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2007 | 1152 | 0.010 |
Why?
|
| France | 1 | 2002 | 108 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 1323 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 610 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2004 | 588 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2002 | 383 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2013 | 8223 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2004 | 1178 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 4938 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 12926 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 3101 | 0.010 |
Why?
|
| DNA Replication | 1 | 2003 | 744 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2003 | 785 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2004 | 786 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 5377 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 13310 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2004 | 3005 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 2803 | 0.010 |
Why?
|
| Prognosis | 1 | 2015 | 21713 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 1688 | 0.010 |
Why?
|
| Vaccination | 1 | 2002 | 1123 | 0.010 |
Why?
|
| Incidence | 1 | 2002 | 5673 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 6942 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 3869 | 0.010 |
Why?
|